SEC Company Response from Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771) (HEPA) — Feb 13, 2019
Hepion Pharmaceuticals, Inc. (HEPA, CTRVP) (CIK 0001583771)
Date: Feb. 13, 2019 · CIK: 0001583771 · Accession: 0001104659-19-007753
AI Filing Summary & Sentiment
File numbers found in text: 333-229534
Letter
ContraVir Pharmaceuticals, Inc.
399 Thornall Street
Edison, NJ 08837
February 13, 2019
VIA EDGAR
United States Securities
and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Todd Schiffman
Re:
ContraVir Pharmaceuticals, Inc.
Form S-3
File No. 333-229534
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), ContraVir Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Standard Time, on Thursday, February 14, 2019, or as soon thereafter as possible.
Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
Thank you,
CONTRAVIR PHARMACEUTICALS, INC.
By:
/s/ Robert Foster
Name:
Robert Foster
Title:
Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm ContraVir Pharmaceuticals, Inc. 399 Thornall Street Edison, NJ 08837 February 13, 2019 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Todd Schiffman Re: ContraVir Pharmaceuticals, Inc. Form S-3 File No. 333-229534 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), ContraVir Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Standard Time, on Thursday, February 14, 2019, or as soon thereafter as possible. Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request. Thank you, CONTRAVIR PHARMACEUTICALS, INC. By: /s/ Robert Foster Name: Robert Foster Title: Chief Executive Officer